BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Position in Pfizer Inc. $PFE

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 22.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,881,478 shares of the biopharmaceutical company’s stock after selling 1,680,468 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.10% of Pfizer worth $149,382,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute purchased a new stake in Pfizer in the second quarter worth about $30,000. True Wealth Design LLC increased its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $27.84.

Pfizer Trading Down 1.8%

NYSE:PFE opened at $26.87 on Friday. The company has a market cap of $152.78 billion, a PE ratio of 19.76 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a 50 day simple moving average of $25.94 and a two-hundred day simple moving average of $25.29. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the business posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.